A Drug 100 Times Stronger Than Fentanyl Is Spreading. New York's DEA Is Racing to Contain It.
Carfentanil, a veterinary tranquilizer 100 times more potent than fentanyl, has surged across the U.S. with DEA labs identifying it 1,400 times in 2025—up from just 54 in 2022.
The phone call came days before Thanksgiving. Kelley Nalewaja remembers collapsing to the floor when she heard the word "autopsy." Her 36-year-old son Michael, an electrician in Alaska who had successfully completed rehab as a teenager, had been found dead. The cause: a lethal mixture of fentanyl and carfentanil that he may have mistaken for cocaine.
"Even if somebody had been there prepared with Narcan—even if somebody had called 911 in time—he was not going to survive," Nalewaja told the Associated Press.
Her story is becoming grimly familiar across the United States. Carfentanil, a synthetic opioid originally developed as a veterinary tranquilizer for large animals like elephants, has surged back into the illicit drug supply with devastating consequences. The Drug Enforcement Administration's own labs identified the substance 1,400 times in drug seizures during 2025—a staggering increase from just 145 detections in 2023 and 54 in 2022.
What Makes Carfentanil Different
To understand the threat, consider the numbers. Fentanyl, already notorious for its lethality, is approximately 50 to 100 times more potent than morphine. Carfentanil makes fentanyl look mild by comparison—it is roughly 10,000 times more potent than morphine and 100 times stronger than fentanyl itself.
A lethal dose of fentanyl fits on the tip of a pencil. A lethal dose of carfentanil is smaller than a poppy seed—equivalent to just a few grains of salt. The DEA's New York division, which covers operations from Maine to Virginia, has been tracking the substance with growing alarm.
"This is probably one of the most significant threats we've seen in some time," said Frank Tarentino, the special agent in charge of the DEA's New York division, in an interview with ABC7 New York. "You're talking about not even a grain of salt that could be potentially lethal."
Tarentino's team has access to one of the largest drug analysis laboratories in the country, located in New York City. It is there that chemists have documented the shift: while fentanyl seizures are slightly decreasing, carfentanil appearances are climbing steadily.
Why Now? The Supply Chain Shift
The resurgence of carfentanil coincides with a crackdown thousands of miles away. In recent years, the Chinese government has implemented stricter regulations on the sale of precursor chemicals used to manufacture fentanyl. Those regulations, while partially successful, appear to have triggered an unintended consequence.
According to DEA intelligence bulletins reviewed by the Associated Press, traffickers in Mexico—where many synthetic opioids are produced—may be turning to carfentanil to boost the potency of weakened fentanyl batches. Some reports suggest Mexican cartels are experimenting with producing carfentanil directly, while others indicate the substance is being procured from China-based vendors who skirt regulations by advertising on online forums in other countries.
The manufacturing process itself presents extreme hazards. "You can't just dabble in this," Tarentino noted. "This is not some mad scientist on Reddit you're going to get to go out to a rudimentary laboratory in Mexico to make carfentanil."
Yet someone is making it—and distributing it widely. The substance is being detected in powder form and pressed into counterfeit pills designed to mimic legitimate prescription medications like oxycodone.
The Naloxone Problem
Perhaps the most concerning aspect of the carfentanil surge involves the limitations of existing overdose reversal tools. Naloxone, sold under the brand name Narcan, has been credited with saving countless lives during the fentanyl era. It works by displacing opioids from receptors in the brain, temporarily reversing the respiratory depression that causes fatal overdoses.
But carfentanil's extreme potency creates a unique challenge. Medical literature has documented cases of "resistance to reversal with standard doses of naloxone" when dealing with fentanyl analogs like carfentanil. The substance's half-life—approximately six hours—also exceeds that of naloxone's effects, creating a risk of "rebound" overdose where victims initially respond to treatment only to slip back into respiratory arrest.
"Experts say that even multiple high doses of naloxone might not be enough to reverse an overdose when carfentanil is involved," the Associated Press reported.
This limitation strikes at the heart of harm reduction strategies that have shown promise in reducing overdose deaths. New York State has distributed nearly 700,000 naloxone kits and nearly 20 million fentanyl test strips in recent years. Governor Kathy Hochul's administration has highlighted these efforts as key drivers behind the state's progress in addressing the opioid epidemic. But test strips cannot detect carfentanil with reliability, and naloxone may not be sufficient to reverse its effects.
New York's Exposure
While carfentanil has been detected nationwide, New York has not been spared. According to CDC data published in the Morbidity and Mortality Weekly Report, New York was among seven states reporting between 10 and 19 overdose deaths involving illegally manufactured fentanyls and carfentanil during a recent surveillance period. Florida and West Virginia reported 20 or more.
The New York State Department of Health issued a public health alert in June 2024 after carfentanil was detected in drug samples from Central New York. State Health Commissioner Dr. James McDonald emphasized the importance of community drug checking programs that can identify dangerous substances before they are consumed.
"Carfentanil is a veterinary drug that is no longer marketed because it is so dangerous," McDonald stated at the time. "The Department partners with community programs that provide access to drug checking so these dangerous substances are identified before they are used."
The Broader Context: Progress and Peril
The carfentanil surge arrives at a paradoxical moment in the overdose crisis. After years of record-breaking death tolls, the United States is finally seeing sustained improvement. Overdose deaths have fallen for more than two consecutive years—the longest decline in decades. Preliminary CDC data suggests deaths have dropped by nearly 27% from their peak, equivalent to approximately 81 lives saved daily.
Fentanyl seizures have also declined significantly. U.S. Customs and Border Protection reported that fentanyl seizures plunged to about 12,000 pounds in 2025—less than half the amount seized in 2023.
Public health experts attribute this progress to multiple factors: the wider availability of naloxone, expanded access to medication-assisted treatment for opioid use disorder, and regulatory pressure on precursor chemical markets. But they caution against complacency.
"Even though there's a noticeable drop, it is not in any way, shape or form an indicator that this crisis is over," Tarentino emphasized.
Sara Carter, President Trump's drug policy advisor, struck a similar note: "Anyone who takes a pill that is not prescribed to them by their doctor is playing a game of Russian roulette with their life."
What Comes Next
The DEA has requested a $362 million budget increase focused specifically on cartel-driven fentanyl trafficking, a sign that federal law enforcement views the synthetic opioid threat as ongoing despite recent declines in deaths. The agency's ability to track emerging substances like carfentanil through its laboratory network will be critical to understanding—and potentially disrupting—the evolving supply chain.
For New Yorkers, the message from health officials remains consistent: assume any illicit drug may contain potent synthetic opioids, carry naloxone even though it may not be fully effective against carfentanil, and never use alone. The state's network of overdose prevention centers, syringe service programs, and drug checking services represent frontline defenses against an enemy that keeps changing its chemical formula.
Kelley Nalewaja, still grieving her son, put it in stark terms that echo the warnings of public health officials: "It's not an OD; it's not an overdose. It's a murder weapon."
The drug supply, it seems, has entered a new phase—one where the progress of recent years faces its most dangerous test yet.
Written by
MTNYC Editorial TeamThe MTNYC Editorial Team is a group of healthcare writers, researchers, and addiction specialists dedicated to providing accurate, compassionate, and evidence-based information about addiction treatment and recovery resources in New York State.
